Johnson & Johnson today announced plans to initiate the first head-to-head study comparing FcRn blockers for patients with generalized myasthenia gravis (gMG), which aims to affirm IMAAVYtm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback